Literature DB >> 6345724

Inhibition of rabbit brain prolyl endopeptidase by n-benzyloxycarbonyl-prolyl-prolinal, a transition state aldehyde inhibitor.

S Wilk, M Orlowski.   

Abstract

Prolyl endopeptidase cleaves peptide bonds on the carboxyl side of proline residues within a peptide chain. The enzyme readily degrades a number of neuropeptides including substance P, neurotensin, thyrotropin-releasing hormone, and luteinizing hormone-releasing hormone. The finding that the enzyme is inhibited by benzyloxycarbonyl-prolyl-proline, with a Ki of 50 microM, prompted the synthesis of benzyloxycarbonyl-prolyl-prolinal as a potential transition state analog inhibitor. Rabbit brain prolyl endopeptidase was purified to homogeneity for these studies. The aldehyde was found to be a remarkably potent inhibitor of prolyl endopeptidase with a Ki of 14 nM. This Ki is more than 3000 times lower than that of the corresponding acid or alcohol. By analogy with other transition state inhibitors, it can be assumed that binding of the prolinal residue to the S1 subsite and the formation of a hemiacetal with the active serine of the enzyme greatly contribute to the potency of inhibition. The specificity of the inhibitor is indicated by the finding that a variety of proteases were not affected at concentrations 150 times greater than the Ki for prolyl endopeptidase. The data indicate that benzyloxycarbonyl-prolyl-prolinal is a specific and potent inhibitor of prolyl endopeptidase and that consequently it should be of value in in vivo studies on the physiological role of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345724     DOI: 10.1111/j.1471-4159.1983.tb11815.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

1.  Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney.

Authors:  Nadja Grobe; Khalid M Elased; David R Cool; Mariana Morris
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-07       Impact factor: 4.310

2.  Benzyloxycarbonylprolylprolinal, a transition-state analogue for prolyl oligopeptidase, forms a tetrahedral adduct with catalytic serine, not a reactive cysteine.

Authors:  A Kahyaoglu; K Haghjoo; F Kraicsovits; F Jordan; L Polgar
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

3.  Inhibitors of prolyl endopeptidase: characterization of the pharmacophoric pattern using conformational analysis and 3D-QSAR.

Authors:  T Langer; C G Wermuth
Journal:  J Comput Aided Mol Des       Date:  1993-06       Impact factor: 3.686

4.  Slow tight-binding inhibition of prolyl endopeptidase by benzyloxycarbonyl-prolyl-prolinal.

Authors:  A V Bakker; S Jung; R W Spencer; F J Vinick; W S Faraci
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

5.  Benzyloxycarbonyl-proline-prolinal (ZPP): Dual complementary roles for neutrophil inhibition.

Authors:  D W Russell; M Hardison; K R Genschmer; T Szul; P E Bratcher; M Abdul Roda; X Xu; L Viera; J E Blalock; A Gaggar; B D Noerager
Journal:  Biochem Biophys Res Commun       Date:  2019-08-07       Impact factor: 3.575

6.  Enzymatic inactivation of bradykinin by rat brain neuronal perikarya.

Authors:  E A DelBel; A P Padovan; G J Padovan; O Z Sellinger; A R Martins
Journal:  Cell Mol Neurobiol       Date:  1989-09       Impact factor: 5.046

7.  Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide.

Authors:  M T Schiavone; R A Santos; K B Brosnihan; M C Khosla; C M Ferrario
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

8.  Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents.

Authors:  Nicholas Wallingford; Bertrand Perroud; Qian Gao; Anna Coppola; Erika Gyengesi; Zhong-Wu Liu; Xiao-Bing Gao; Adam Diament; Kari A Haus; Zia Shariat-Madar; Fakhri Mahdi; Sharon L Wardlaw; Alvin H Schmaier; Craig H Warden; Sabrina Diano
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

9.  Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity.

Authors:  Ruoli Bai; Michael C Edler; Peter L Bonate; Terry D Copeland; George R Pettit; Richard F Ludueña; Ernest Hamel
Journal:  Mol Pharmacol       Date:  2008-10-16       Impact factor: 4.436

Review 10.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.